Erhalten Sie eine woechentliche Zusammenfassung der neuesten psychedelischen Forschung, neuer Studien und Plattform-Updates direkt in Ihren Posteingang.
Kein Spam, nie. Jederzeit abbestellbar.
Substanzprofil
N,N-Dimethyltryptamin (DMT) ist ein natürlich vorkommendes Tryptamin, das in zahlreichen Pflanzen und Tieren vorkommt und als eines der potentesten kurzwirksamen Psychedelika gilt. Als Rauchform erzeugt es innerhalb von Sekunden eine intensive, aber kurze psychedelische Erfahrung von 15-30 Minuten. In der traditionellen Ayahuasca-Zubereitung wird DMT mit einem MAO-Hemmer (typischerweise Banisteriopsis caapi) kombiniert, was die orale Bioverfügbarkeit ermöglicht und die Wirkdauer auf 4-6 Stunden verlängert. Die Forschung untersucht DMT und Ayahuasca bei Depression, Suchterkrankungen und posttraumatischen Belastungsstörungen.
Rapid-onset serotonin 2A activation producing intense visual phenomena
Modulates calcium signaling and cellular stress response
Harmine/harmaline inhibit MAO-A enabling oral DMT bioavailability
Berichtete subjektive Effekte basierend auf klinischen und Community-Daten
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants.
Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind.
Randomized and Blind Evaluation of the Efficacy of a Full-Spectrum Oral Cannabis sativa Oil Extract, Standardized Based on CBD-A, CBD and THC-A, THC in Canines with Chronic Osteoarthritis.
Immunogenicity of Hepatitis B Virus Vaccination in Relapsing-Remitting Multiple Sclerosis Patients Under Immunocompromising Treatment.
Exploring Colombian medicinal flora used in indigenous and campesino health systems for neuropsychiatric disorders and neuropharmacological potential: an ethnopharmacological review.
Reduced peripheral serotonin levels in women with multiple sclerosis: associations with underweight status, treatment duration, and use of interferon beta 1a.
Comparative assessment of treatment switching in patients with multiple sclerosis receiving cladribine tablets versus fingolimod, dimethyl fumarate, and teriflunomide.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants.
Long-term outcomes of cladribine tablets in multiple sclerosis: Treatment completion, persistence, and subsequent therapy transitions in Southeast Europe.
Evaluating use of disease-modifying therapies for multiple sclerosis using claims data.
N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine.
Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis.
Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.
Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.
Beyond the toad's kiss: Mapping acute 5-MeO-DMT effects on brain connectivity across sex and dose using awake rat neuroimaging.
Streamlining Eligibility Assessment for Alzheimer's Disease-Modifying Therapies: Prediction of MMSE Scores Using the Digital Clock and Recall.
Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.
Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.
International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.
Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.
Analysis of herpes zoster cases in multiple sclerosis patients treated with disease-modifying drugs: insights from the EudraVigilance database.
Determinants of change in disease-modifying drugs in patients with multiple sclerosis: A registry-based study.
LGBTQ+ Ayahuasca Retreat Experience is Associated with Benefits to Mental Health, Quality of Life, and Spiritual Well-Being: A Prospective, Naturalistic Study.
The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naïve patients with multiple sclerosis.
Association of cytokine levels with treatment duration and patient family history in Egyptian multiple sclerosis patients.
Effects of disease modifying therapy on cognitive proficiency in pediatric-onset multiple sclerosis (POMS).
Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling.
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice.
Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Filipino Patients With Multiple Sclerosis: A Single-Center Retrospective Case Series.
Challenging The Diagnosis of Multiple Sclerosis: Histopathological Insights Gained Through Brain Biopsies.
Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies.
Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation.
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression.
Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder.
Influence of Therapeutic Failure on the Psychosocial Experience in Multiple Sclerosis
A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.
The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health.
The Signature of Alzheimer's Disease in Subjective Cognitive Decline
Oral Semaglutide in Patients With Alzheimer's Disease
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.
Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.
Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.
Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.
Serotonergic psychedelics for depression: A comprehensive overview.
Clinical pharmacology.
Human neuroimaging: fMRI.
Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.